Pharma Aids (DHA:PHARMAID) EPS (Basic): BDT-931.46 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:PHARMAID Pharma Aids Ltd DHA:PHARMAID
73 GF Score
Price BDT644.70
GF Value BDT758.56
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Pharma Aids EPS (Basic)?

Pharma Aids DHA:PHARMAID -2.55% 73 EPS (Basic) is BDT-931.46 as of Mar. 2026. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT758.56 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Pharma Aids's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was BDT611.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-931.46.

Pharma Aids's EPS (Diluted) for the three months ended in Mar. 2026 was BDT611.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-931.46.

Pharma Aids's EPS without NRI for the three months ended in Mar. 2026 was BDT611.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -931.07.

During the past 12 months, Pharma Aids's average EPS without NRIGrowth Rate was -303.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 22.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Pharma Aids's highest 3-Year average EPS without NRI Growth Rate was 75.60% per year. The lowest was -50.00% per year. And the median was 19.30% per year.

Pharma Aids  (DHA:PHARMAID) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Pharma Aids EPS (Basic) Related Terms

Pharma Aids EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Pharma Aids's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Aids EPS (Basic) Chart

Pharma Aids Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.11 11.14 -2.05 19.61 20.45

Pharma Aids Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 445.00 -1,556.55 6.81 7.28 611.00
DHA:PHARMAID
73GF Score
Pharma Aids Ltd DHA:PHARMAID
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Aids EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Pharma Aids's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(63.815-0)/3.120
=20.45

Pharma Aids's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(19.076-0)/3.120
=6.11

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-931.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of BDT-931.46 mean?
Pharma Aids (DHA:PHARMAID) has a EPS (Basic) of BDT-931.46 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pharma Aids and its competitors.
Is Pharma Aids' EPS (Basic) too high?
Pharma Aids' current EPS (Basic) is BDT-931.46. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' EPS (Basic) compare to ISRG and BDX?
Pharma Aids' EPS (Basic) of BDT-931.46 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pharma Aids and its competitors. Pharma Aids's current EPS (Basic) is BDT-931.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT758.56, compared to a current price of BDT644.70 — trading 15% below its estimated fair value. The current EPS (Basic) is BDT-931.46. Pharma Aids' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current EPS (Basic) is BDT-931.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued. The current stock price of BDT644.70 is trading 15% below its estimated GF Value™ of BDT758.56. GuruFocus considers Pharma Aids to be Modestly Undervalued.

Key valuation signals for DHA:PHARMAID:

  • EPS (Basic): BDT-931.46
  • GF Value™: BDT758.56 vs. price of BDT644.70 (15% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharma Aids Business Description

Address 345 Segun Bagicha, 1st Floor, Ramna, Dhaka, BGD, 1000
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score

Get the complete analysis for DHA:PHARMAID

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT644.70
Price
BDT758.56
GF Value